Surovatamig Biosimilar Bispecific Antibody (CD3 × CD19) for Research

Cat No.: GMP-Bios-INN-1401

Anti-CD3D&CD3E therapeutic antibody (Pre-made Surovatamig biosimilar,Bispecific Mixed Domains ((H-gamma4_L-kappa)_VH-G4(h-CH2-CH3))) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Surovatamig (development codes AZD-0486/TNB-486) is a bispecific antibody targeting CD3 and CD19. It is developed by AstraZeneca and TeneoBio and TeneoTwo for Follicular lymphoma, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma in Phase III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1401-1mg 1mg
GMP-Bios-INN-1401-10mg 10mg
GMP-Bios-INN-1401-100mg 100mg
GMP-Bios-INN-1401-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Surovatamig biosimilar, Bispecific Mixed Domains ((H-gamma4_L-kappa)_VH-G4(h-CH2-CH3)), Anti-CD3D&CD3E;CD19 Antibody: Anti-CD3 Delta/CD3D/CD3d/T-cell surface glycoprotein CD3 delta chain therapeutic antibody
INN Name Surovatamig
Target CD3D&CD3E;CD19
Format Bispecific Mixed Domains ((H-gamma4_L-kappa)_VH-G4(h-CH2-CH3))
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4;G4
VD LC Kappa;na
Highest_Clin_Trial (Jan '20) Phase-III
Est. Status Active
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended na
Companies AstraZeneca;TeneoBio;TeneoTwo
Conditions Approved na
Conditions Active Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma
Conditions Discontinued na
Production na
Development Tech na